|Bid||10.08 x 1100|
|Ask||10.09 x 800|
|Day's Range||10.02 - 10.58|
|52 Week Range||7.48 - 14.14|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.63|
Puma Biotechnology reports inducement awards granted in May 2021 as required under Nasdaq Listing Rule 5635(c)(4) .
Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.
Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.